is your aging company working on aging?

Most longevity companies don't pursue aging. They pursue a disease.

This isn't because founders don't care about aging. It's because there's no regulatory path for aging itself -- no approved endpoint, no reimbursement code, no established criteria for what "treating aging" even means in a clinical context. So the practical move is to pick an age-related disease, develop a drug against it, and hope the mechanism translates back to aging broadly (under the assumption that aging will eventually become an approved indication, mirroring something like the obesity story).

The logic makes sense on paper. Age-related diseases share upstream biology with aging. If your drug hits a root cause of aging, it should show efficacy in a disease driven by that cause. Get the drug approved, generate revenue, then expand into aging later.

But I keep coming back to a tension in this strategy that I think deserves more scrutiny.

Drug development takes a decade, sometimes longer. Getting a drug from target to clinic to approval is one of the hardest things a team can do, and the history of pharma is full of well-funded, well-staffed programs that failed anyway. The companies that succeed tend to be the ones with genuine obsession for the problem they're solving (I saw this firsthand during my time at BridgeBio). They know the patient population inside out. They understand the disease biology at a level that lets them adapt when trials don't go as expected -- because trials rarely go as expected.

So what happens when the founding team's real passion is aging, but they're spending a decade on idiopathic pulmonary fibrosis or a rare genetic condition? The disease becomes a vehicle, not a mission. That matters more than people acknowledge.

Take genetic diseases as an example. Many longevity companies are drawn to them because they offer orphan drug designation, smaller trial sizes, and clear unmet need. But the best therapeutic approaches for genetic diseases tend to operate at or near the source of the mutation (the mechanism is localized). A gene therapy correcting a single loss-of-function variant in a pediatric population is solving a fundamentally different problem than slowing systemic decline in a healthy 30-year-old. The biology might share a keyword, but the intervention logic diverges.

Cancer is another instructive case. Aging is the single greatest risk factor for cancer, and there's real mechanistic overlap (cellular senescence, genomic instability, immune decline). But most successful cancer drugs work by exploiting specific vulnerabilities in tumor biology, not by reversing the aging processes that gave rise to the tumor. An anti-PD-1 checkpoint inhibitor is brilliant oncology. It's not an aging drug. The fact that aging and cancer share upstream biology doesn't mean a drug optimized for one will meaningfully move the other. There's a fundamental gap between what works in a rare genetic condition and what a 30-year-old needs to delay functional decline (independent of disease).

This leads to an uncomfortable counterfactual. If a founder truly cares about aging, and they have a decade of time and capital to deploy -- what's the highest-value use of those resources? Is it pursuing a disease indication where the drug may underperform for patients (because it was optimized around an aging thesis rather than disease biology) and may not translate to aging anyway? Or would that decade be better spent going one of two other directions -- either committing fully to the disease and serving those patients with genuine focus (this is tremendously valuable, but hard to do if it's not your mission!), or investing in the basic research and regulatory groundwork needed to eventually test aging interventions in healthy people?

I don't think bridging is always wrong (there's a spectrum in terms of the translatability of disease biology to aging). But I think the field treats it as the default path without enough scrutiny of the counterfactual. And when the timescale is a decade, patients deserve drugs built for them and founders deserve to spend their years on what they believe matters most.